^
    Back
    Association details:
    Biomarker:KDR rs1870377
    Cancer:Breast Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    NPJ Breast Cancer
    Title:

    A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients

    Published date:
    03/21/2022
    Excerpt:
    Median PFS for favorable genetic profile was 16.8 vs. the 10.6 months of unfavorable genetic profile (p = 0.0011)....Median OS for the favorable genetic profile was 39.6 vs. 28 months of unfavorable genetic profile (p = 0.0103)....The pharmacogenetic statistical interaction between VEGF-A rs833061 and VEGFR-2 rs1870377 genotypes may identify a population of bevacizumab-treated patients with a better PFS.
    Secondary therapy:
    paclitaxel
    DOI:
    10.1038/s41523-022-00400-6